125 / 140
Principios generales de tratamiento particularizado de los sarcomas de partes blandas según histología
>
125
42. García-del-Muro X, López-Pousa A, Maurel J, et al. Randomized Phase II Study Comparing Gemcitabine Plus
Dacarbazine Versus Dacarbazine Alone in Patients With Previously Treated Soft Tissue Sarcoma: A Spanish
Group for Research on Sarcomas Study. J Clin Oncol 2011;29(18):2528-33.
43. Demetri GD, Chawla SP, von Mehren M, et al: Efficacy and safety of trabectedin in patients with advanced
or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a
randomized phase II study of two different schedules. J Clin Oncol 2009;27:4188-96.
44. Talbot SM, Keohan ML, Hesdorffer M, et al. A phase II trial of temozolomide in patients with unresectable or
metastatic soft tissue sarcoma. Cancer 2003;98:1942-6.
45. O'Cearbhaill R, Zhou Q, Iasonos A, at al. Treatment of advanced uterine leiomyosarcoma with aromatase in-
hibitors. Gynecol Oncol 2010;116:424-9.
46. Wade K, Quinn MA, Hammond I, et al. Uterine sarcoma: steroid receptors and response to hormonal therapy.
Gynecol Oncol 1990;39:364-7.
47. McCluggage WG, Varma M, Weir P, et al. Leiomyosarcoma in patient receiving tamoxifen therapy. Acta Ob-
stet Gynel Scand 1996;75:593-5.
Sarcoma pleomórfico
48. Van Glabbeke M, van Oosterom AT, Oosterhuis JW, et al. Prognostic Factors for the Outcome of Chemother-
apy in Advanced Soft Tissue Sarcoma: An Analysis of 2,185 Patients Treated With Anthracycline-Containing
First-Line Regimen. An European Organization for Research and Treatment of Cancer Soft Tissue and Bone
Sarcoma Group Study. J Clin Oncol 1999;17:150-7, by American Society of Clinical Oncology.
49. Maki R, D’Adamo D, Keohan M, et al. Phase II Study of Sorafenib in Patients With Metastatic or Recurrent
Sarcomas. J Clin Oncol 2009;27:3133-40.
Sarcoma sinovial
50. Edmonson JH, Ryan LM, Blum RH, et al. Randomized comparison of doxorubicin alone versus ifosfamide
plus doxorubicin or mitomycin plus doxorubicin and cisplatin against advanced soft tissue sarcomas. J Clin
Oncol 1993;11:1269-75.
51. Rosen G, Forschen Ch, Lowenbraun S, et al. Synovial Sarcoma. Uniform response of metastasis of high dose
ifosfamide. Cancer 1994;73(10):2506-11.
52. Le Cesne A, Antoine E, Spielmann M, et al. High dose ifosfamide: circumvention of resistance to standard-
dose ifosfamide in advanced soft tissue sarcomas. J Clin Oncol 1995;13:1600-8.
53. Sanfilippo R, Dileo P, Blay JY, et al. Trabectedin in advanced synovial sarcomas: a multicenter retro-
spective study from four European institutions and the Italian Rare Cancer Network. Anti-Cancer Drugs
2015;26:678-81.
54. Robbins PF, Kassim SH, Tran TL, et al. A pilot trial using lymphocytes genetically engineered with an
NY-ESO-1-reactive T-cell receptor: long-term follow-up and correlates with response. Clin Cancer Res
2015;21:1019-27.
Tumor maligno de la vaina nerviosa periférica
55. Kroep JR, Ouali M, Gelderblom H, et al. First-line chemotherapy for malignant peripheral nerve sheath tumor
(MPNST) versus other histological soft tissue sarcoma subtypes and as a prognostic factor for MPNST: an
EORTC Soft Tissue and Bone Sarcoma Group study. Ann Oncol 2011;22:207-14.
56. Steins MB, Serve H, Zuhlsdor M, et al. Carboplatin/etoposide induces remission of metastasised ma-
lignant peripheralnerve tumours (malignant schwannoma) refractory to first-line therapy. Oncol Rep
2002;9:627-30.
57. Kinebuchi Y, Noguchi W, Igawa Y, et al. Recurrent retroperitoneal malignant nerve sheath tumor associated
with neurofibromatosis type 1 responding to carboplatin and etoposide combined chemotherapy. Int J Clin
Oncol 2005;10:353-6.